Gefitinib Tablet trade name Iressa, marketed by AstraZeneca and Tevais is advised for treating certain breast, lung and other cancers. This medication acts by interrupting signalling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR.
- As Gefitinib Tablet is a selective chemotherapeutic agent, its tolerability profile is better than previous cytotoxic agents
- Adverse drug reactions (ADRs) are acceptable for a potentially fatal disease
- Acne is reported very commonly
- Other common adverse effects (≥1% of patients) include: diarrhoea, nausea, vomiting, anorexia, stomatitis, dehydration, skin reactions, paronychia, asymptomatic elevations of liver enzymes, asthenia, conjunctivitis, blepharitis
- Infrequent adverse effects (0.1–1% of patients) include: interstitial lung disease, corneal erosion, aberrant eyelash and hair growth